Case Study Suggests Milk Thistle Is Potent Against Hep C
Case Study in Liver International
The case study being reviewed was published in a February 2015 edition of the journal Liver International. The US-based study evaluated intravenous silibinin in a 44-year-old woman with Hepatitis C genotype 1 who developed a severe psychiatric adverse reaction to a previous course of pegylated interferon and ribavirin (the antiquated standard of care for Hepatitis C). The experimental treatment consisted of combing the following:
- 1,200 mg/day of silibinin
- 1,200 mg/day of ribavirin
- 6,000 iu/day of Vitamin D
After the first three weeks of treatment, the patient’s viral load led to a prediction of achieving a sustained virologic response (the measurement correlated with a cure) in 34 weeks. Provided with this information, the patient agreed to complete 34 weeks of treatment and was rewarded with a sustained virologic response – without any adverse reactions. The authors concluded that silibinin-based therapy is a treatment option for patients who do not respond to or cannot receive other Hepatitis C drugs.
http://www.cancer.gov/cancertopics/pdq/cam/milkthistle/Patient/page2, Milk Thistle (PDQ®), Retrieved April 12, 2015, National Cancer Institute, 2015.
http://www.ncbi.nlm.nih.gov/pubmed/21605016, Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy, Eurich D, et al, Retrieved April 12, 2015, Experimental and Clinical Transplantation, February 2011.
http://www.ncbi.nlm.nih.gov/pubmed/25251042, Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics, Dahari H, et al, Retrieved April 12, 2015, Liver International, February 2015.
New Pain-Free Alternative to Biopsy: evaluation, treatment and follow-up options for Hepatitis C patients
Coverage Restrictions for Hepatitis C Drugs